1. Home
  2. CAPR vs TILE Comparison

CAPR vs TILE Comparison

Compare CAPR & TILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$24.05

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Interface Inc.

TILE

Interface Inc.

HOLD

Current Price

$30.28

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
TILE
Founded
2005
1973
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CAPR
TILE
Price
$24.05
$30.28
Analyst Decision
Strong Buy
Buy
Analyst Count
8
1
Target Price
$41.38
$32.00
AVG Volume (30 Days)
1.3M
321.2K
Earning Date
11-10-2025
02-24-2026
Dividend Yield
N/A
0.26%
EPS Growth
N/A
33.41
EPS
N/A
1.92
Revenue
$11,130,509.00
$1,372,471,000.00
Revenue This Year
N/A
$7.55
Revenue Next Year
$16,329.74
$4.73
P/E Ratio
N/A
$16.10
Revenue Growth
N/A
5.11
52 Week Low
$4.30
$17.24
52 Week High
$40.37
$31.35

Technical Indicators

Market Signals
Indicator
CAPR
TILE
Relative Strength Index (RSI) 49.28 62.26
Support Level $23.53 $27.81
Resistance Level $25.44 $31.35
Average True Range (ATR) 1.73 0.85
MACD -0.95 0.12
Stochastic Oscillator 12.97 69.77

Price Performance

Historical Comparison
CAPR
TILE

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About TILE Interface Inc.

Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.

Share on Social Networks: